HK1255689A1 - Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease - Google Patents

Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease Download PDF

Info

Publication number
HK1255689A1
HK1255689A1 HK18114837.8A HK18114837A HK1255689A1 HK 1255689 A1 HK1255689 A1 HK 1255689A1 HK 18114837 A HK18114837 A HK 18114837A HK 1255689 A1 HK1255689 A1 HK 1255689A1
Authority
HK
Hong Kong
Prior art keywords
fatty liver
alcoholic fatty
liver disease
triacetyl
liver
Prior art date
Application number
HK18114837.8A
Other languages
English (en)
Chinese (zh)
Inventor
朱海波
史会杰
史會杰
Original Assignee
北京谷神生命健康科技有限公司
江蘇天士力帝益藥業有限公司
中国医学科学院药物研究所
中國醫學科學院藥物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京谷神生命健康科技有限公司, 江蘇天士力帝益藥業有限公司, 中国医学科学院药物研究所, 中國醫學科學院藥物研究所 filed Critical 北京谷神生命健康科技有限公司
Publication of HK1255689A1 publication Critical patent/HK1255689A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
HK18114837.8A 2015-12-31 2016-12-28 Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease HK1255689A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201511034199.0 2015-12-31
CN201511034199 2015-12-31
PCT/CN2016/112623 WO2017114413A1 (zh) 2015-12-31 2016-12-28 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Publications (1)

Publication Number Publication Date
HK1255689A1 true HK1255689A1 (en) 2019-08-23

Family

ID=59224622

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114837.8A HK1255689A1 (en) 2015-12-31 2016-12-28 Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease

Country Status (11)

Country Link
US (1) US11058703B2 (https=)
EP (1) EP3398604A4 (https=)
JP (1) JP7382716B2 (https=)
KR (1) KR102676056B1 (https=)
CN (2) CN118178446A (https=)
AU (1) AU2016383376B2 (https=)
CA (1) CA3010097C (https=)
HK (1) HK1255689A1 (https=)
RU (1) RU2759916C2 (https=)
WO (1) WO2017114413A1 (https=)
ZA (1) ZA201805080B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用
CA3102404A1 (en) 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
CN111821313A (zh) * 2019-04-17 2020-10-27 江苏天士力帝益药业有限公司 三乙酰基-3-羟基苯基腺苷在制备抑制心脏纤维化的药物中的应用
CN114869901B (zh) * 2022-05-06 2023-10-27 安徽医科大学 马鞭草苷在治疗酒精性肝损伤药物中的应用
CN117599076A (zh) * 2023-11-15 2024-02-27 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005132812A (ja) 2003-10-08 2005-05-26 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物の分画物およびその用途
CN100427534C (zh) * 2004-03-19 2008-10-22 四川大学 聚合物型含磷阻燃剂及其制备方法和用途
JP2007210926A (ja) 2006-02-08 2007-08-23 Tokyo Univ Of Pharmacy & Life Science ピラジンカルボン酸化合物からなる薬剤、及び食餌
CN101712709A (zh) * 2008-10-06 2010-05-26 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
JP5688229B2 (ja) 2010-03-19 2015-03-25 国立大学法人名古屋大学 肝保護作用を有するタンパク質、肝障害予防・保護用化合物のスクリーニング方法
CN102125580A (zh) 2011-01-17 2011-07-20 泰山医学院 三乙酰基-3-羟基苯基腺苷thpa在制药中的应用
AU2012245996B2 (en) * 2011-04-22 2016-09-01 Pfizer Inc. Pyrazolospiroketone derivatives for use as acetyl-CoA carboxylase inhibitors
AU2013204500A1 (en) 2012-09-21 2014-04-10 Barbara Jane Badenoch-Jones Novel AMPK agonist compositions and methods of use
CN103191145A (zh) 2013-03-27 2013-07-10 南京理工大学 腺苷及其衍生物在防治药物性肝损伤中的应用
CN104211747B (zh) * 2013-05-29 2018-09-25 中国医学科学院药物研究所 5’-磷酸-n6-(3-羟基苯基)腺苷的制备及医药用途
US9827222B2 (en) 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
CN104546887B (zh) * 2013-10-09 2018-10-30 中国医学科学院药物研究所 虫草素衍生物治疗炎症疾病的用途
CN105663152A (zh) * 2014-11-19 2016-06-15 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备改善胰岛素抵抗及相关疾病中的应用
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用

Also Published As

Publication number Publication date
KR20180100152A (ko) 2018-09-07
CN106943420A (zh) 2017-07-14
KR102676056B1 (ko) 2024-06-19
JP7382716B2 (ja) 2023-11-17
CA3010097A1 (en) 2017-07-06
AU2016383376B2 (en) 2022-07-28
US11058703B2 (en) 2021-07-13
EP3398604A1 (en) 2018-11-07
RU2018126158A (ru) 2020-01-31
WO2017114413A1 (zh) 2017-07-06
ZA201805080B (en) 2019-10-30
CN118178446A (zh) 2024-06-14
CA3010097C (en) 2023-08-22
RU2759916C2 (ru) 2021-11-18
US20190022120A1 (en) 2019-01-24
JP2019500379A (ja) 2019-01-10
RU2018126158A3 (https=) 2020-03-11
EP3398604A4 (en) 2019-06-19
AU2016383376A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
AU2016383376B2 (en) Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
US20230138576A1 (en) Use of dihydroberberine or its derivatives to enhance muscle function
KR20220157313A (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
CN117599036A (zh) 隐绿原酸在制备治疗和/或预防非酒精性脂肪肝产品中的用途
CN106176773A (zh) 盐酸小檗碱和水苏糖组成的组合物及其应用
CN115894584B (zh) 小檗碱与野黄芩苷形成的盐,其制备方法和应用
KR20150130352A (ko) 지방간 질환을 치료하는 방법
CN112370496A (zh) 枸杞叶有效成分在制备预防或治疗肝纤维化药物中的应用
US9943560B2 (en) Medical compositions containing liquorice extracts with synergistic effect
CN111686239B (zh) 抗真菌化合物的应用
CN103690535A (zh) 盐酸去亚甲基小檗碱在制备预防和/或治疗肝纤维化药物中的应用
CN114788825A (zh) Magl抑制剂的医药用途
CN111000852B (zh) 苦蘵中睡茄内酯提取物在制备预防或治疗非酒精性脂肪性肝病的药物中应用
CN113181178A (zh) 盐酸去亚甲基四氢小檗碱在制备预防或治疗疼痛药物中的应用
CN115554285B (zh) 3-去甲基秋水仙碱在药物中的应用
TW202239401A (zh) 正丁基苯酞於促進脂肪褐變、以及預防或治療脂肪肝及相關肝病變之應用
CN106943408B (zh) 四甲基尿酸预防和治疗糖尿病的应用
CN103735549A (zh) 盐酸去亚甲基小檗碱在制备治疗非酒精性脂肪肝病药物中的应用
CN103550211A (zh) 盐酸小檗碱在制备预防和/或治疗急慢性酒精性肝病药物中的应用
CN117100739B (zh) 负调节Nrf2信号通路的小分子组合物及其应用
KR101613252B1 (ko) 아르기나아제 억제제를 함유하는 비만 및 지방간 예방 또는 치료용 조성물
CN111374978B (zh) 沙利度胺在制备改善地中海贫血患者肝功能损害的药物组合物中的应用
KR20080094466A (ko) 대사증후군 치료용 약제 조성물
CN120983451A (zh) 柯里拉京在制备预防或治疗代谢相关脂肪性肝病产品中的应用
KR20260033973A (ko) 오에노테인 b를 포함하는 대사이상 간 질환의 예방 또는 치료용 조성물